Response to press comment

4 Jul 2006 10:19

ReGen Therapeutics PLC04 July 2006 For immediate release ReGen Therapeutics Plc 4 July 2006 Statement in response to press comment ReGen Therapeutics Plc ("ReGen") announces that in the light of recent presscomment it is in discussions regarding a licensing agreement for thecommercialization of ColostrininTM in North America. These discussions have beenin progress for some time. A further announcement will be made when appropriate. Further information: Andrew MarshallGreycoat CommunicationsTel: 020 7960 6007Mobile: 07785 297111 This information is provided by RNS The company news service from the London Stock Exchange